Daniel Loeb
Third Point
Daniel Loeb Precigen Inc stake
total: 588
Third Point PGEN trades
- Total transactions:
- 7
- New positions:
- 1
- Sold out:
- 1
- Added:
- 2
- Reduced:
- 3
- Held since:
- 2013 Q3
- Held for:
- 9 quarters
- Latest activity:
- 2015 Q4
According to 2026 Q2 report, Daniel Loeb doesn't hold any Precigen Inc (PGEN) shares. To date, the estimated cost basis is nearly $23.4 for "buy" trades and estimated average "sell" price is $32.48. Third Point first purchased PGEN in 2013 Q3, initially acquiring about 2.15M shares. Since the initial investment in Precigen Inc (PGEN), Third Point has made 6 more transactions.
When did Daniel Loeb sell Precigen Inc (PGEN)?
Daniel Loeb sold off the entire Precigen Inc (PGEN) position in 2015 Q4.
When did Daniel Loeb buy Precigen Inc (PGEN)?
Daniel Loeb first invested in Precigen Inc (PGEN) in 2013 Q3 at the reported quarter-end price of $22.84 per share.
What's the cost basis of Third Point's PGEN stake?
The estimated cost basis for Precigen Inc (PGEN) stake is around $23.40 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $23.40
- Weighted AVG sell price:
- $32.48
Daniel Loeb's historical trades in Precigen Inc
7 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2015 Q4
|
0.00%
|
$31.80
|
-100% (-1,500,000)
|
|||
|
2015 Q3
|
0.46%
|
$31.80
|
-44.44% (-1,200,000)
|
|||
|
2015 Q1
|
1.22%
|
$45.37
|
-6.90% (-200,000)
|
|||
|
2014 Q2
|
0.90%
|
$25.13
|
-3.33% (-100,000)
|
|||
|
2014 Q1
|
1.24%
|
$26.29
|
+18.15% (+460,800)
|
|||
|
2013 Q4
|
1.11%
|
$23.08
|
+18.07% (+388,608)
|
|||
|
2013 Q3
|
1.20%
|
$22.84
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.